UNIGE document Scientific Article
previous document  unige:25523  next document
add to browser collection

Nouveaux traitements de l’hépatite C : quelles cibles, quel calendrier?

Published in Revue médicale suisse. 2011, vol. 7, no. 307, p. 1683-8
Abstract The hepatitis C virus (HCV) is a global major health burden, its response to current treatment is unfortunately inadequate, in particular for genotype 1. Two new direct acting antivirals, that inhibit NS3/4A viral protease, will soon be available on the Swiss market: telaprevir and boceprevir. These substances increase the rate of sustained viral response, in HCV genotype 1 infected patients, when coadministered with pegylated interferon and ribavirin. However, these new molecules may lead to serious adverse effects and drug interactions with which the specialist and the primary care physician must be familiar.
Keywords Antiviral Agents/therapeutic useHepatitis C/drug therapyHumansOligopeptides/therapeutic useProline/analogs & derivatives/therapeutic use
PMID: 21987876
Full text
Article (Published version) (835 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/numero-307-page-1683.htm
Research group Etudes et traitement de l'hépatite C et B (554)
(ISO format)
GOOSSENS, Nicolas, NEGRO, Francesco. Nouveaux traitements de l’hépatite C : quelles cibles, quel calendrier?. In: Revue médicale suisse, 2011, vol. 7, n° 307, p. 1683-8. https://archive-ouverte.unige.ch/unige:25523

210 hits

0 download


Deposited on : 2013-01-15

Export document
Format :
Citation style :